List view / Grid view
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
Researchers discovered that measuring the concentrations of IL-18 in an individual’s blood could estimate future risk of stroke.
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
As we move towards more generalised AI models, neural networks and natural language interfaces, we’re starting to see machine learning take the place of higher order reasoning and data analysis “sense making.” Traditional scientific inquiry has typically been about asking specific questions of a specific model system under specific conditions.…
Researchers discovered that smooth muscle cells can change into cancer-like cell types and worsen atherosclerosis.
Researchers have revealed that genetically enhanced expression of GSDMB causes a disturbed interferon-response.
The study’s findings explain the genetic differences in people’s blood pressure, which could lead to personalised medicine approaches.
Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several…
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
Dr Laura Figulla is the CEO of mbiomics. Laura co-founded mbiomics which is dedicated to unlocking the true value of the microbiome by developing next-generation live biotherapeutics (LBPs). Throughout her career, Laura has combined her entrepreneurial spirit with her diverse academic background in business, economics, and medicine to build companies that…
The new organoids demonstrate a greater diversity of TECs in culture and are capable of maturing T cells.
Adult anxious behaviour in offspring may be related to the early life proinflammatory state caused by the absence of elevated XCL1.
In this episode, we discuss the current advantages and limitations of using organoids, as well as where the field is heading.
In animal studies, the new vaccine construct outperformed another PNAG-vaccine delivery system currently in human trials.
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools…
